Posted by Michael Wonder on 03 Mar 2021
Oblato announces fast track designation of OKN-007 for diffuse intrinsic pontine glioma from the FDA
3 March 2021 - Oblato announces that the FDA granted fast track designation of OKN-007, the proprietary drug for diffuse intrinsic pontine glioma.
In addition to the fast track designation, Oblato has already received rare paediatric disease designation for diffuse intrinsic pontine glioma.
